NCT06343064View on ClinicalTrials.gov

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Non-Small-Cell Lung Cancer
Interventions
DRUG

Vebreltinib

Phase Ib is a dose escalation study, the initial dose of Vebreltinib is 100mg/150mg/200mg,according to the result of Phase Ib, will confirm the RP2D.

DRUG

PLB1004

Phase Ib is a dose escalation study, the initial dose of PLB1004 is 80mg/160mg,according to the result of Phase Ib, will confirm the RP2D.

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Avistone Biotechnology Co., Ltd.

INDUSTRY